Commentary on "A Roadmap for the Prevention of Dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): A New Approach to the Prevention of Alzheimer's Disease

Alzheimers Dement. 2009 Mar;5(2):114-21. doi: 10.1016/j.jalz.2009.01.008.

Abstract

Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer's disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial nature of AD, it seems logical to initiate multidomain interventions to examine their potential synergistic effects. The MAPT Study aims to evaluate the efficacy of a multidomain intervention (nutritional, physical, and cognitive training) and omega 3 treatment in the prevention of cognitive decline in frail elderly persons aged 70 years or over. The study also collects imaging and biological data that could be used in future AD prevention and treatment trials.

Methods: The MAPT Study is a 3-year, randomized, controlled trial conducted by university hospital practitioners specializing in memory disorders in four French cities (Bordeaux, Limoges, Montpellier, and Toulouse). The study plans to enroll 1200 frail elderly subjects on the basis of at least one of the following criteria: subjective memory complaint spontaneously expressed to a general practitioner, limitation in one instrumental activity of daily living (IADL), and slow walking speed. To demonstrate the protective effect of interventions, subjects are randomized into one of the following four groups: omega 3 alone, multidomain intervention alone, omega 3 plus multidomain intervention, or placebo (n = 300 each). The principal outcome measure is a change in cognitive function at 3 years, as determined by the Grober and Buschke Test.

Conclusions: The MAPT Study is the first preventive trial involving multidomain interventions. Final results should be available in 2013.

Trial registration: ClinicalTrials.gov NCT00672685.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Alzheimer Disease / diet therapy
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / prevention & control*
  • Biomarkers
  • Brain / drug effects*
  • Brain / metabolism
  • Brain / physiopathology
  • Cognition Disorders / diet therapy
  • Cognition Disorders / drug therapy
  • Cognition Disorders / prevention & control
  • Cognitive Behavioral Therapy / methods*
  • Data Collection
  • Disease Progression
  • Exercise Therapy / methods*
  • Fatty Acids, Omega-3 / administration & dosage*
  • Humans
  • Neuropsychological Tests
  • Outcome Assessment, Health Care / methods
  • Patient Selection
  • Research Design
  • Sample Size

Substances

  • Biomarkers
  • Fatty Acids, Omega-3

Associated data

  • ClinicalTrials.gov/NCT00672685